Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
10.01
-0.18 (-1.77%)
Nov 19, 2026, 4:00 PM EST - Market closed
Corvus Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Corvus Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $31.5. The average 1-year stock price forecast is 214.69% higher than the current stock price, while the lowest is $27 (+169.73%) and the highest is $42 (+319.58%).
Price Target: $31.5 (+214.69%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Corvus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 6 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $27 | Buy | Maintains | $27 | +169.73% | Nov 11, 2026 |
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Reiterates $33 | Buy | Reiterates | $33 | +229.67% | Nov 6, 2026 |
| Barclays | Barclays | Buy Maintains $28 | Buy | Maintains | $28 | +179.72% | Nov 6, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $30 → $27 | Buy | Maintains | $30 → $27 | +169.73% | Oct 29, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $40 | Buy | Maintains | $40 | +299.60% | May 15, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.58M
EPS This Year
-0.80
from -0.54
EPS Next Year
-1.10
from -0.80
EPS and Forward PE are based on non-GAAP adjusted numbers.